Prognostic significance of CDKN2A/B hemizygous deletion in IDH-mutant astrocytomas: a systematic review and meta-analysis
Brain Tumor Pathology · 17.03.2026
DOI: 10.1007/s10014-026-00536-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Brain Tumor Pathology, online erschienen am 17.03.2026. Verfasst von Satoshi Nakasu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurosurgery, Omi Medical Center, Yabase-cho 1660, Kusatsu, Shiga, 525-8585, Japan. neuro-nakasu@kfx.biglobe.ne.jp. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
The prognostic significance of CDKN2A/B hemizygous deletion (HemD) in IDH-mutant astrocytomas (A-IDHm) remains unclear. We conducted a systematic review and WHO grade-specific meta-analysis of primary tumors following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Effect sizes included hazard ratios (HRs) and restricted mean survival time (RMST) for overall survival. The pooled frequency of HemD in grade 2 A-IDHm was 13.8% (95% confidence interval [CI]: 8.5–21.7%; 12 studies; I2 = 23.6%), lower than that in grade 3 tumors (25.2% [CI: 20.5–30.5%; 12 studies; I2 = 0%]) and grade 4 tumors with CDKN2A/B non-homozygous deletion (29.5% [CI: 23.3–36.6%]; 11 studies; I2 = 0%). Stratification by WHO grade revealed a significant association in grade 2 tumors (pooled HR [pHR]: 1.98 [CI: 1.03–3.80]; four studies; 369 patients; P = 0.04; I2 = 0%), but no significant association in grade 3 (pHR: 1.78 [CI: 0.99–3.20]; five studies, 239 patients; P = 0.054; I2 = 0%) or grade 4 tumors (pHR: 1.39 [CI: 0.85–2.26]; five studies; 192 patients; P = 0.18; I2 = 0%). The RMST difference reached statistical significance only in WHO grade 2 tumors, suggesting a potential prognostic effect of HemD in low-grade A-IDHm.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neurosurgery, Omi Medical Center, Yabase-cho 1660, Kusatsu, Shiga, 525-8585, Japan. neuro-nakasu@kfx.biglobe.ne.jp.
- Department of Neurosurgery, Shiga University of Medical Science, Ohtsu, Japan. neuro-nakasu@kfx.biglobe.ne.jp.
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Laboratory of Neuropathology and Molecular Biology, Fleni, Buenos Aires, Argentina.
- Division of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Japan.
- Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan.
Zitieren
APA
Nakasu, S., Deguchi, S., Mezmezian, M., Mitsuya, K., Notsu, A., & Nakasu, Y. (2026). Prognostic significance of CDKN2A/B hemizygous deletion in IDH-mutant astrocytomas: a systematic review and meta-analysis. Brain Tumor Pathology. https://doi.org/10.1007/s10014-026-00536-4
Vancouver
Nakasu S, Deguchi S, Mezmezian M, Mitsuya K, Notsu A, Nakasu Y. Prognostic significance of CDKN2A/B hemizygous deletion in IDH-mutant astrocytomas: a systematic review and meta-analysis. Brain Tumor Pathology. 2026. doi:10.1007/s10014-026-00536-4
BibTeX
@article{Nakasu2026,
author = {Nakasu, Satoshi and Deguchi, Shoichi and Mezmezian, Mónica and Mitsuya, Koichi and Notsu, Akifumi and Nakasu, Yoko},
title = {Prognostic significance of CDKN2A/B hemizygous deletion in IDH-mutant astrocytomas: a systematic review and meta-analysis},
journal = {Brain Tumor Pathology},
year = {2026},
doi = {10.1007/s10014-026-00536-4}
}
EUVIMED